Department of Radiation Oncology, University of Rochester, Rochester, NY.
Department of Radiation Oncology, University of Rochester, Rochester, NY.
Clin Lung Cancer. 2020 May;21(3):195-203. doi: 10.1016/j.cllc.2019.02.017. Epub 2019 Mar 4.
Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with patients with first primary NSCLC.
Individuals with histologically confirmed NSCLC diagnosed after nonmetastatic squamous-cell carcinoma of the head and neck (HNC-NSCLC; n = 3597) were identified in Surveillance, Epidemiology, and End Results 18 registries (1988-2013). OS and baseline characteristics were compared in patients with first primary NSCLC (NSCLC-1; n = 365,551) in the same registries.
Squamous NSCLC was more common in HNC-NSCLC (n = 745 [64.1%] localized, n = 833 [71.9%] regional, and n = 811 [63.5%] distant) than in the NSCLC-1 (n = 30,901 [38.3%] localized, n = 50,557 [48.2%] regional, and n = 53,720 [29.8%] distant; P < .001). The leading cause of death in HNC-NSCLC was NSCLC (n = 2183; 60.6%), and median OS after localized, regional, and distant NSCLC diagnosis was 2.50 years, 1.17 years, and 5 months, respectively. For NSCLC-1, median OS was 4.58 years, 1.58 years, and 6 months, respectively. These differences were significant (P < .001). In multivariable analysis, a history of HNC remained associated with worse OS for localized (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.29-1.51; P < .001), regional (HR, 1.26; 95% CI, 1.19-1.35; P < .001) and distant (HR, 1.11; 95% CI, 1.04-1.18; P < .01) stage NSCLC.
A history of HNC adversely affects OS in patients who subsequently develop NSCLC. This OS decrement might have implications for NSCLC surveillance and NSCLC therapy selection in this population.
回顾性研究表明,有头颈部癌症(HNC)病史的患者发生第二原发性肺癌的风险增加。尚无基于人群的研究比较过 HNC 后发生第二原发性非小细胞肺癌(NSCLC)与初发 NSCLC 患者的总生存(OS)结局。
在 Surveillance, Epidemiology, and End Results 18 登记处(1988-2013 年)中确定了经组织学证实的非转移性头颈部鳞状细胞癌(HNC-NSCLC;n=3597)后诊断为 NSCLC 的个体。在同一登记处中,比较了初发 NSCLC(NSCLC-1;n=365551)患者的 OS 和基线特征。
HNC-NSCLC 中更常见的是鳞状 NSCLC(n=745 [64.1%]局限性,n=833 [71.9%]区域性,n=811 [63.5%]远处转移),而 NSCLC-1 中更常见的是(n=30901 [38.3%]局限性,n=50557 [48.2%]区域性,n=53720 [29.8%]远处转移;P<.001)。HNC-NSCLC 中导致死亡的主要原因是 NSCLC(n=2183;60.6%),局限性、区域性和远处 NSCLC 诊断后的中位 OS 分别为 2.50 年、1.17 年和 5 个月。对于 NSCLC-1,中位 OS 分别为 4.58 年、1.58 年和 6 个月。这些差异具有统计学意义(P<.001)。多变量分析显示,HNC 病史与局限性(风险比[HR],1.40;95%置信区间[CI],1.29-1.51;P<.001)、区域性(HR,1.26;95% CI,1.19-1.35;P<.001)和远处(HR,1.11;95% CI,1.04-1.18;P<.01)分期 NSCLC 的 OS 不良相关。
HNC 病史会对随后发生 NSCLC 的患者的 OS 产生不利影响。这种 OS 下降可能对该人群的 NSCLC 监测和 NSCLC 治疗选择具有重要意义。